In 2012, we increased our knowledge of the molecular portrait of breast cancer. The BOLERO-2 and CLEOPATRA trials led to the approval of everolimus and pertuzumab; and the EMILIA trial will likely result in the approval of T-DM1. Some of these findings represent a paradigm shift in the way we think about the biology and management of breast cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors
Breast Cancer Research Open Access 30 May 2014
-
Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells
British Journal of Cancer Open Access 18 March 2014
-
The expression and clinical significance of HERC4 in breast cancer
Cancer Cell International Open Access 14 November 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
Baselga, J. et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 28, 1138–1144 (2010).
Baselga, J. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109–119 (2012).
Krop, I. E. et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 30, 3234–3241 (2012).
Burris, H. A. 3rd et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 29, 398–405 (2011).
Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012).
Miller, T. W., Balko, J. M. & Arteaga, C. L. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J. Clin. Oncol. 29, 4452–4461 (2011).
Bachelot, T. et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J. Clin. Oncol. 30, 2718–2724 (2012).
Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520–529 (2012).
Acknowledgements
This work was supported in part by National Cancer Institute 1K23CA121994 (A. M. Gonzalez-Angulo), ASCO Career Development Award (A. M. Gonzalez-Angulo), Komen for the Cure Catalystic Award KG090341 (A. M. Gonzalez-Angulo), and National Cancer Institute through The University of Texas MD Anderson's Cancer Center Support Grant (P30 CA016672).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M. Chavez-MacGregor receives research funding from Novartis Oncology. A. M. Gonzalez-Angulo is a consultant and receives research funding from Genentech and Novartis Oncology.
Rights and permissions
About this article
Cite this article
Chavez-MacGregor, M., Gonzalez-Angulo, A. New drugs, new knowledge, new targets. Nat Rev Clin Oncol 10, 75–76 (2013). https://doi.org/10.1038/nrclinonc.2012.236
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.236
This article is cited by
-
Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors
Breast Cancer Research (2014)
-
Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells
British Journal of Cancer (2014)
-
The expression and clinical significance of HERC4 in breast cancer
Cancer Cell International (2013)